isoquinoline6,7-diol hydrobromide salt | 113884-76-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: isoquinoline6,7-diol hydrobromide salt
• 英文别名: 6,7-dihydroxyisoquinolin-2-ium bromide；6,7-dihydroxyisoquinoline hydrobromide；Isoquinolin-2-ium-6,7-diol;bromide
• CAS: 113884-76-7
• 化学式: BrH*C₉H₇NO₂
• 分子量: 242.072
• InChiKey: OFRUFXYUVKMBPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.22
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.6
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  isoquinoline6,7-diol hydrobromide salt 以64%的产率得到
  参考文献：
  名称：

  NAKAGAVA, SUSUMU;OMINEH, KEHNITI;USIDZIMA, JOSISUKEH

  摘要：

  DOI：
• 作为产物：
  描述：

  6,7-dimethoxyisoquinoline hydrochloride 以 氢溴酸 为溶剂， 以97.6%的产率得到isoquinoline6,7-diol hydrobromide salt
  参考文献：
  名称：

  Cephalosporin derivatives, processes for their preparation and

  摘要：

  该化合物的化学式为：##STR1## 其中R.sup.6是氢原子或烷酰基，或其盐，以及其制备方法。

  公开号：

  US04782155A1

文献信息

• [EN] CEPHEM COMPOUNDS WITH LATENT REACTIVE GROUPS AND METHODS OF USING AND MAKING SAME<br/>[FR] COMPOSÉS CÉPHÈMES COMPRENANT DES GROUPES RÉACTIFS LATENTS ET MÉTHODES D'UTILISATION ET PROCÉDÉS DE FABRICATION DE CEUX-CI
  申请人：SUTTON LARRY D

  公开号：WO2020206381A1

  公开（公告）日：2020-10-08

  The present application provides novel cephem, penem, and monobactam compounds that exhibit antibiotic activity against both Gram-negative and Gram-positive bacteria, as well as compositions comprising these compounds and methods of using these compounds and compositions to treat bacterial infections.

  本申请提供了新型头孢菌素、青霉素类和单环内酰胺化合物，对革兰氏阴性和革兰氏阳性细菌均表现出抗生素活性，以及包含这些化合物的组合物，以及使用这些化合物和组合物治疗细菌感染的方法。
• Cephem Compounds with Latent Reactive Groups
  申请人：Gladius Pharmaceuticals, Inc.

  公开号：US20190100534A1

  公开（公告）日：2019-04-04

  Cephem and penem compounds having a styrylmethylene moiety at the 3-position in the cephem or penem ring to which a positively charged leaving group is bonded and wherein the leaving group contains a vicinal diol or is bonded to a unsubstituted or substituted catechol. The leaving group can be a positively charge nitrogen leaving group. Cephems include cephalosporins, cephamycins, carbacephems, and oxacephems. Penems include penems, carbapenems and oxapenems. Preferred cephems are cephalosporins. Preferred penems are carbapenems. Compounds exhibit antibiotic activity against Gram-negative bacteria and/or Gram-positive bacteria. Compounds exhibit antibiotic activity against bacteria which exhibit multi-drug resistance. Compounds of the invention exhibit antibiotic activity against bacterial strains which produce extended spectrum beta-lactamases (ESBL), which produce AmpC beta-lactamases or which produce a carbapenemase. Pharmaceutical compositions comprising one or more cephems or penems or methods of treatment of bacterial infections with such compounds and compositions.

  具有在头孢菌素或青霉烷素环中3位处具有苯乙烯亚甲基基团的头孢菌素和青霉烷素化合物，其中正电离子离去基团与离去基团中含有邻二醇或连接到未取代或取代过的邻苯二酚。离去基团可以是正电离子离去基团。头孢菌素包括头孢菌素、头孢菌烷、卡巴头孢菌素和氧头孢菌素。青霉烷素包括青霉烷素、碳青霉烷素和氧青霉烷素。首选头孢菌素是头孢菌素。首选青霉烷素是碳青霉烷素。化合物对革兰氏阴性细菌和/或革兰氏阳性细菌表现出抗生素活性。化合物对表现出多重耐药性的细菌表现出抗生素活性。本发明的化合物表现出抗生素活性，对产生扩展谱β-内酰胺酶（ESBL）、产生AmpCβ-内酰胺酶或产生碳青霉烷酶的细菌菌株表现出抗生素活性。包括一种或多种头孢菌素或青霉烷素的制药组合物或使用这些化合物和组合物治疗细菌感染的方法。
• Cephalosporin derivatives, processes for their preparation and antibacterial agents
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：EP0238060A2

  公开（公告）日：1987-09-23

  The compound having the formula: wherein R is a straight chain, branched chain or cyclic lower alkyl, a lower alkenyl or a lower alkynyl group which may be substituted by a carboxyl group, and R¹ is hydrogen atom or an acetyl group; or a pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, processes for the preparation thereof, and an antibacterial agent containing it. Also disclosed are a compound having the formula: wherein R⁶ is a hydrogen atom or an alkanoyl group, or a salt thereof and a process thereof.

  式中 R 为可被羧基取代的直链、支链或环状低级烷基、低级烯基或低级炔基，R¹ 为氢原子或乙酰基的化合物；或其药学上可接受的盐、生理上可水解的酯或溶液、其制备工艺以及含有该化合物的抗菌剂。 还公开了一种化合物，其式为： 其中 R⁶ 是氢原子或烷酰基，或其盐及其工艺。
• Antibiotic C-3 catechol-substituted cephalosporin compounds, compositions and use thereof
  申请人：Bristol-Myers Squibb Company

  公开号：EP0474049A1

  公开（公告）日：1992-03-11

  This invention relates to novel cephalosporin derivatives of the formula wherein    R¹ is hydrogen, a straight, branched, or cyclic lower alkyl group having up to six carbon atoms or a radical of the formula in which R³ and R⁴ are each independently hydrogen, methyl or ethyl, or R³ and R⁴, taken together with the carbon atom to which they are attached, may be a cycloalkylidene ring containing from 3 to 5 carbon atoms;    R² is a radical selected from the group consisting of wherein R⁵ is hydrogen or acetyl; R⁶, R⁷ and R⁸ each are independently C₁₋₅ alkyl; n is 1 or 2; and y is 1 to 5. In another aspect, this invention relates to compounds of formula I and their nontoxic pharmaeutically acceptable salts, physiologically hydrolyzable esters or solvates. Representative compounds of this invention were selected for testing and were shown to display potent antibacterial activity.

  本发明涉及式如下的新型头孢菌素衍生物 式中 R¹为氢、具有最多六个碳原子的直链、支链或环状低级烷基或式中的一个基团 其中 R³ 和 R⁴ 各自独立地为氢、甲基或乙基，或 R³ 和 R⁴ 连同其所连接的碳原子可为含有 3 至 5 个碳原子的亚环烷基环； R² 是选自以下组成的基团 其中 R⁵ 是氢或乙酰基；R⁶、R⁷ 和 R⁸ 各自独立地是 C₁₋₅ 烷基；n 是 1 或 2；以及 y 是 1 至 5。 在另一方面，本发明涉及式 I 化合物及其无毒的药物学上可接受的盐、生理上可水解的酯或溶液。 本发明选择了具有代表性的化合物进行测试，结果表明这些化合物具有很强的抗菌活性。
• NAKAGAWA, SUSUMU;OTAKE, NORIKAZU;USHIZIMA, RYOSUKE
  作者：NAKAGAWA, SUSUMU、OTAKE, NORIKAZU、USHIZIMA, RYOSUKE

  DOI：——

  日期：——